


PHARMACEUTICAL 2023



Organogenesis Holdings Inc. Rank 156 of 446





PHARMACEUTICAL 2023



Organogenesis Holdings Inc. Rank 156 of 446

The relative strengths and weaknesses of Organogenesis Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organogenesis Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Organogenesis Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 149%, being 106% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	222,609
Cost of Goods Sold	105,019
Intangible Assets	49,561
Liabilities, Current	75,023
Liabilities, Non-Current	42,436
Other Assets	74,726
Other Compr. Net Income	0
Other Expenses	4,750
Other Liabilities	66,231
Other Net Income	-2,022
Other Revenues	450,893
Property and Equipment	102,463
Research and Development	39,762
Selling, General and Administrative Expense	283,808

Output Variable	Value in 1000 USD
Assets	449,359
Liabilities	183,690
Expenses	433,339
Revenues	450,893
Stockholders Equity	265,669
Net Income	15,532
Comprehensive Net Income	15,532
Economic Capital Ratio	149%

